Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (481-490 of 560) with videos related to

Pageof 56
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2017
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused UpdateIan Krop, Nofisat Ismaila, Fabrice Andre, et al.
Cancer|April 8, 2011
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerSiqing Fu, Wei Hu, Revathy Iyer, et al.
Cancers|March 6, 2021
A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian CancerJohannes F Fahrmann, Ehsan Irajizad, Makoto Kobayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologueGary J Kelloff, Robert C Bast, Donald S Coffey, et al.
Oncogene|June 7, 2011
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathwaysD B Badgwell, Z Lu, K Le, et al.
Journal of the National Cancer Institute|October 16, 1996
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markersD F Hayes, R C Bast, C E Desch, et al.
Breast Cancer Research : BCR|September 4, 2007
Correlation between CpG methylation profiles and hormone receptor status in breast cancersWeiwei Feng, Lanlan Shen, Sijin Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2019
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORxFabrice Andre, Nofisat Ismaila, N Lynn Henry, et al.
BMC Cancer|October 28, 2016
Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer modelsArgentina Ornelas, Christopher R McCullough, Zhen Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2016
A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to PaclitaxelJinhua Zhou, Albandri Alfraidi, Shu Zhang, et al.
Pageof 56

Showing results (481-490 of 560) with videos related to

Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2017
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused UpdateIan Krop, Nofisat Ismaila, Fabrice Andre, et al.
Cancer|April 8, 2011
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerSiqing Fu, Wei Hu, Revathy Iyer, et al.
Cancers|March 6, 2021
A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian CancerJohannes F Fahrmann, Ehsan Irajizad, Makoto Kobayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologueGary J Kelloff, Robert C Bast, Donald S Coffey, et al.
Oncogene|June 7, 2011
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathwaysD B Badgwell, Z Lu, K Le, et al.
Journal of the National Cancer Institute|October 16, 1996
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markersD F Hayes, R C Bast, C E Desch, et al.
Breast Cancer Research : BCR|September 4, 2007
Correlation between CpG methylation profiles and hormone receptor status in breast cancersWeiwei Feng, Lanlan Shen, Sijin Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2019
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORxFabrice Andre, Nofisat Ismaila, N Lynn Henry, et al.
BMC Cancer|October 28, 2016
Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer modelsArgentina Ornelas, Christopher R McCullough, Zhen Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2016
A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to PaclitaxelJinhua Zhou, Albandri Alfraidi, Shu Zhang, et al.
Pageof 56